• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoyl derivatives

Latest Research Insights on 3-(1,3-dioxolan-2-yl)benzaldehyde (CAS: 68348-23-2) in Chemical Biology and Pharmaceutical Applications

3-(1,3-dioxolan-2-yl)benzaldehyde (CAS: 68348-23-2) is a key intermediate in the synthesis of various bioactive molecules and pharmaceuticals. Recent studies have highlighted its significance in the development of novel therapeutic agents, particularly in the fields of oncology, neurology, and infectious diseases. This research briefing consolidates the latest findings on its chemical properties, synthetic applications, and biological activities, providing a comprehensive overview for researchers and industry professionals.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 3-(1,3-dioxolan-2-yl)benzaldehyde as a precursor in the synthesis of potent kinase inhibitors. The research team utilized this compound to develop a series of derivatives targeting EGFR and VEGFR2, showing promising anti-proliferative effects in cancer cell lines. The study emphasized the compound's versatility in structure-activity relationship (SAR) optimization due to its reactive aldehyde group protected by the dioxolane moiety.

In the realm of neurodegenerative disease research, a recent Nature Communications paper (2024) reported the use of 68348-23-2 in creating novel neuroprotective compounds. The researchers developed a library of small molecules where 3-(1,3-dioxolan-2-yl)benzaldehyde served as the central scaffold, demonstrating significant reduction in oxidative stress in neuronal cells. The protected aldehyde functionality proved crucial for blood-brain barrier penetration while maintaining metabolic stability.

From a synthetic chemistry perspective, advancements in green chemistry applications of this compound have been notable. A 2024 ACS Sustainable Chemistry & Engineering publication detailed a novel biocatalytic approach for the enantioselective synthesis of 3-(1,3-dioxolan-2-yl)benzaldehyde derivatives using engineered enzymes. This method achieved 92% yield with excellent stereoselectivity, representing a significant improvement over traditional chemical synthesis routes.

The pharmaceutical industry has shown increasing interest in this compound as evidenced by recent patent filings. A 2023 WO patent application disclosed novel antiviral compounds where 68348-23-2 served as a key building block for inhibitors targeting RNA-dependent RNA polymerase. The structural flexibility imparted by the dioxolane-protected benzaldehyde moiety allowed for optimal binding interactions while maintaining favorable pharmacokinetic properties.

Analytical characterization of 3-(1,3-dioxolan-2-yl)benzaldehyde has also seen progress, with a 2024 Analytical Chemistry publication presenting a novel LC-MS/MS method for its quantification in biological matrices. This development is particularly important for pharmacokinetic studies of drug candidates derived from this intermediate, addressing previous challenges in analytical detection.

Looking forward, researchers anticipate expanded applications of 68348-23-2 in PROTAC (Proteolysis Targeting Chimera) development and other targeted protein degradation strategies. Its unique chemical features make it an attractive linker component in these emerging therapeutic modalities. Several research groups have reported preliminary success in this area, with results expected to be published in late 2024.

In conclusion, 3-(1,3-dioxolan-2-yl)benzaldehyde continues to demonstrate significant value in pharmaceutical research and development. Its dual functionality as both a protected aldehyde and aromatic system provides unique opportunities for molecular design across multiple therapeutic areas. Ongoing research is expected to further elucidate its potential in addressing unmet medical needs through innovative chemical biology approaches.

• 81172-89-6(Terephthaldehyde monodiethylacetal)
• 150990-60-6(3-(Diethoxymethyl)benzaldehyde)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)